First patients sought for groundbreaking 'Living Drug' trial targeting tough cancers
NCT ID NCT07488923
Summary
This is the first study in people to test the safety and early effects of an experimental cell therapy called ML261. It is for adults with advanced small cell lung cancer or certain related neuroendocrine cancers that have come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target cancer, and infuse them back to fight the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.